CARDIOPROGRESS
Foundation for the advancement of cardiology

Quadpill Strategy Gains Ground in Hypertension Several new antihypertensive agents are reshaping the therapeutic strategies for patients with uncontrolled or resistant hypertension. Agents such as baxdrostat, the first selective aldosterone synthase inhibitor, and aprocitentan, a dual endothelin receptor A and B antagonist, are paving the way for new drug combinations and a more personalized approach to blood pressure control.

Heart Risks Rise, Care Lags: New Stats Expose Harsh Truths Researchers compiled a national data report on the burden, quality of care, and mortality trends for major cardiovascular risk factors and conditions in the US.

Your Heart May Be Older Than You Think Some people are said to have old souls. Some may have old hearts, too. Many Americans, particularly men with less education, lower income, and those from certain minority groups, have a “heart age” that is much older than what the calendar may indicate.

Lp(a) Levels: When and Why It’s Clinically Relevant The presence of high lipoprotein (a), or Lp(a), levels increases the risk for cardiovascular disease. Incorporating Lp(a) screening into clinical practice may significantly impact patient outcomes.

APOE4 May Raise Brain Bleed Risk in Apixaban Users With AF Carriers of the apolipoprotein E epsilon 4 (APOE ε4) allele had a threefold higher risk for intracranial hemorrhage (ICH) when taking apixaban for atrial fibrillation (AF) compared with noncarriers, a new study suggested.

Novel Algorithm Transforms Echocardiographic Assessment of Heart Filling Pressures A new algorithm for estimating left ventricular filling pressure (LVFP) by echocardiography reduced indeterminate results to just two cases compared with 38 using previous guidelines, achieving 86% accuracy in 949 patients, a new study found. The algorithm showed particular improvement for patients with normal left ventricular ejection fraction (LVEF), while maintaining similar accuracy for cases of reduced LVEF.

Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals.

The New Playbook for Ditching Dangerous Senior Meds A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.

International Research in Cardiology 2010-2014 Dear colleagues!
The Cardioprogress Foundation presents the book «International Research in Cardiology», which includes the results of the most important international clinical trials presented in 2010-2024. The authors systematized studies in 21 sections, which include risk factors, antiplatelet and anticoagulant therapy, laboratory and instrumental diagnostics, arrhythmia, invasive cardiology, valvular heart diseases, intensive care in cardiology and more.

New Drug Combos Could Cut Heart Failure Mortality by 60% Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference.